[ad_1] Merck’s multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials. The German pharmaceutical company’s phase 3 clinical trials for the drug did not achieve their primary…
Tag: Neurodegenerative Disease Drugs
Alzheimer’s Blockbuster Is Coming, but Slowly
[ad_1] Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. [ad_2] Source link
Medicare Plans to Cover Alzheimer’s Drugs
[ad_1] Biogen and Eisai’s Leqembi is up for full approval this summer. [ad_2] Source link
Eli Lilly Results Signal Arrival of Blockbuster New Drug Class
[ad_1] Share Listen (2 min) [ad_2] Source link
Eli Lilly Drug Fails to Prevent Alzheimer’s in Study
[ad_1] Business Health Care Health The drug was no better than placebo at averting the condition [ad_2] Source link
Biogen Boss Turns Corner on Alzheimer’s Miscues
[ad_1] The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm. [ad_2] Source link
Collecting Pharma’s Scraps Can Pay Off for This Biotech
[ad_1] Markets Heard on the Street Roivant has built a unique model that allows it to benefit from big pharma’s need to reduce R&D spending [ad_2] Source link
Drugmakers Raise Prices on Nearly 1,000 Medicines but Show Restraint
[ad_1] Health List prices climb by 5.6% on average as new federal law aims to lower drug costs [ad_2] Source link
FDA Seeks More Data on Lilly’s Alzheimer’s Drug Candidate
[ad_1] Business Health Care Health Setback could delay potential commercial introduction by at least several months [ad_2] Source link
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug Aduhelm
[ad_1] Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company. [ad_2] Source link